Stock LUN LUNDBECK
Add to a list
To use this feature you must be a member
Log inSign up

Financials Lundbeck Nasdaq Copenhagen

Equities

LUN

DK0061804697

Pharmaceuticals

Market Closed - Nasdaq Copenhagen
Other stock markets
 10:59:55 2024-04-26 am EDT 		5-day change 1st Jan Change
28.15 DKK +0.72% Intraday chart for Lundbeck +0.90% -18.50%
Apr. 09 H. Lundbeck, Otsuka Pharmaceutical Seek US FDA Nod for PTSD Combination Therapy MT
Apr. 09 Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD CI

Valuation

Fiscal Period: December 2022 2023 2024 2025 2026
Capitalization 1 25,433 31,719 31,709 - -
Enterprise Value (EV) 1 27,464 31,008 27,256 23,602 19,695
P/E ratio 13.5 x 14.2 x 10.8 x 9.51 x 8.53 x
Yield 2.23% 2.14% 2.7% 3.09% 3.61%
Capitalization / Revenue 1.39 x 1.59 x 1.51 x 1.45 x 1.4 x
EV / Revenue 1.51 x 1.56 x 1.3 x 1.08 x 0.87 x
EV / EBITDA 5.89 x 5.49 x 4.53 x 3.65 x 2.83 x
EV / FCF 10.2 x 8.66 x 6.11 x 5.19 x 3.97 x
FCF Yield 9.83% 11.5% 16.4% 19.3% 25.2%
Price to Book 1.24 x 1.47 x 1.33 x 1.19 x 1.07 x
Nbr of stocks (in thousands) 992,840 992,840 992,011 - -
Reference price 2 26.05 32.76 32.92 32.92 32.92
Announcement Date 2/7/23 2/7/24 - - -
1DKK in Million2DKK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 17,036 17,672 16,299 18,246 19,912 21,020 21,870 22,643
EBITDA 1 4,823 4,783 3,720 4,663 5,652 6,014 6,465 6,950
EBIT 1 3,608 1,990 2,010 2,852 3,195 3,984 4,912 5,403
Operating Margin 21.18% 11.26% 12.33% 15.63% 16.05% 18.95% 22.46% 23.86%
Earnings before Tax (EBT) 1 3,481 1,906 1,581 2,474 2,993 3,970 4,544 5,018
Net income 1 2,667 1,581 1,318 1,916 2,290 3,001 3,426 3,845
Net margin 15.66% 8.95% 8.09% 10.5% 11.5% 14.28% 15.66% 16.98%
EPS 2 - - - 1.930 2.310 3.035 3.463 3.861
Free Cash Flow 1 2,169 3,360 1,662 2,699 3,579 4,461 4,550 4,957
FCF margin 12.73% 19.01% 10.2% 14.79% 17.97% 21.22% 20.8% 21.89%
FCF Conversion (EBITDA) 44.97% 70.25% 44.68% 57.88% 63.32% 74.18% 70.37% 71.33%
FCF Conversion (Net income) 81.33% 212.52% 126.1% 140.87% 156.29% 148.65% 132.81% 128.94%
Dividend per Share 2 - - - 0.5800 0.7000 0.8903 1.019 1.190
Announcement Date 2/6/20 2/4/21 2/9/22 2/7/23 2/7/24 - - -
1DKK in Million2DKK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 4,013 4,053 4,372 4,475 4,719 4,680 5,044 4,938 4,952 4,978 5,194 5,232 5,301 5,289 5,534
EBITDA 1 933 440 1,290 1,049 1,414 910 1,845 1,493 1,521 793 1,550 1,574 1,551 1,489 1,674
EBIT 1 526 6 875 622 952 403 1,233 840 891 231 1,060 1,010 1,020 952 1,180
Operating Margin 13.11% 0.15% 20.01% 13.9% 20.17% 8.61% 24.44% 17.01% 17.99% 4.64% 20.42% 19.31% 19.25% 18% 21.32%
Earnings before Tax (EBT) 1 412 -112 528 647 882 417 1,150 785 883 175 1,057 975 951.5 935.5 1,184
Net income 1 321 -2 412 505 688 311 880 600 676 134 875.4 819.2 826.6 678.2 911
Net margin 8% -0.05% 9.42% 11.28% 14.58% 6.65% 17.45% 12.15% 13.65% 2.69% 16.86% 15.66% 15.59% 12.82% 16.46%
EPS 2 - - - 0.5100 0.6900 0.3100 0.8900 0.6000 0.6800 0.1400 0.8132 0.7671 0.7756 0.6702 0.9200
Dividend per Share 2 - - - - - 0.5800 - - - 0.7000 - - - 0.4775 -
Announcement Date 11/10/21 2/9/22 5/11/22 8/17/22 11/9/22 2/7/23 5/10/23 8/16/23 11/8/23 2/7/24 - - - - -
1DKK in Million2DKK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 6,625 3,966 3,043 2,031 - - - -
Net Cash position 1 - - - - 711 4,454 8,108 12,014
Leverage (Debt/EBITDA) 1.374 x 0.8292 x 0.818 x 0.4356 x - - - -
Free Cash Flow 1 2,169 3,360 1,662 2,699 3,579 4,461 4,550 4,957
ROE (net income / shareholders' equity) 26.8% 9.37% 14.2% 16.4% 10.7% 16.1% 15.4% 15.3%
ROA (Net income/ Total Assets) 13.2% 4.4% 7.07% 8.87% 6.12% 8.79% 9.08% 9.26%
Assets 1 20,266 35,893 18,647 21,606 37,429 34,150 37,731 41,533
Book Value Per Share 2 - - - 20.90 22.20 24.80 27.60 30.80
Cash Flow per Share 2 - - - 3.540 4.110 4.720 5.100 5.170
Capex 1 440 477 610 820 501 529 634 566
Capex / Sales 2.58% 2.7% 3.74% 4.49% 2.52% 2.52% 2.9% 2.5%
Announcement Date 2/6/20 2/4/21 2/9/22 2/7/23 2/7/24 - - -
1DKK in Million2DKK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Lundbeck

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
32.92 DKK
Average target price
38.71 DKK
Spread / Average Target
+17.58%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Pharmaceuticals Wholesale

1st Jan change Capi.
MCKESSON CORPORATION Stock McKesson Corporation
+17.35% 71.39B
SINOPHARM GROUP CO. LTD. Stock Sinopharm Group Co. Ltd.
+5.38% 8.59B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD Stock Shanghai Pharmaceuticals Holding Co., Ltd
+6.69% 8.19B
HUADONG MEDICINE CO., LTD Stock Huadong Medicine Co., Ltd
-20.96% 7.91B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD Stock Jointown Pharmaceutical Group Co., Ltd
+17.12% 4.31B
EBOS GROUP LIMITED Stock EBOS Group Limited
-3.38% 3.93B
GALENICA AG Stock Galenica AG
-2.61% 3.86B
CHINA NATIONAL MEDICINES CORPORATION LTD. Stock China National Medicines Corporation Ltd.
+22.08% 3.64B
MEDIPAL HOLDINGS CORPORATION Stock MediPal Holdings Corporation
+7.96% 3.29B
Pharmaceuticals Wholesale
  1. Stock Market
  2. Equities
  3. HLUN B Stock
  4. LUN Stock
  5. Financials Lundbeck